Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report

• Published in: Journal of the American Academy of Dermatology Vol. 38; no. 4; pp. 564 - 568
• Main Authors: Hodak, Emmilia, Yosipovitch, Gil, David, Michael, Ingber, Arieh, Chorev, Liran, Lider, Ofer, Cahalon, Leora, Cohen, Irun R.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.04.1998; Elsevier
• Subjects: Adult; Aged; Biological and medical sciences; Biopsy; Dermatology; Enoxaparin - administration & dosage; Enoxaparin - therapeutic use; Female; Follow-Up Studies; Humans; Lichen Planus - drug therapy; Lichen Planus - pathology; Lichen Planus, Oral - drug therapy; Lichen Planus, Oral - pathology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Psoriasis. Parapsoriasis. Lichen; Skin - pathology; Skin, nail, hair, dermoskeleton; Time Factors; Treatment Outcome; Human; Low molecular weight heparin; Skin disease; Chemotherapy; Treatment; Lichen planus

Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monoth...